U.S. markets open in 5 hours 35 minutes
  • S&P Futures

    3,853.00
    +33.75 (+0.88%)
     
  • Dow Futures

    31,949.00
    +173.00 (+0.54%)
     
  • Nasdaq Futures

    12,500.75
    +203.50 (+1.65%)
     
  • Russell 2000 Futures

    2,224.50
    +23.70 (+1.08%)
     
  • Crude Oil

    65.21
    +0.16 (+0.25%)
     
  • Gold

    1,694.60
    +16.60 (+0.99%)
     
  • Silver

    25.66
    +0.39 (+1.55%)
     
  • EUR/USD

    1.1899
    +0.0047 (+0.39%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    24.79
    +0.13 (+0.53%)
     
  • GBP/USD

    1.3897
    +0.0075 (+0.54%)
     
  • USD/JPY

    108.6290
    -0.2720 (-0.25%)
     
  • BTC-USD

    53,960.30
    +3,991.02 (+7.99%)
     
  • CMC Crypto 200

    1,087.62
    +63.41 (+6.19%)
     
  • FTSE 100

    6,726.88
    +7.75 (+0.12%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     

Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference

  • Oops!
    Something went wrong.
    Please try again later.
Kiniksa Pharmaceuticals, Ltd.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st, 2020 at 8:50 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These pipeline assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

Every Second Counts!™

Kiniksa Investor and Media Contact
Mark Ragosa
(781) 430-8289
mragosa@kiniksa.com